SCREENING FOR COMPOUNDS THAT MODULATE GPR3-MEDIATED BETA-ARRESTIN SIGNALING AND AMYLOID BETA PEPTIDE GENERATION

The present invention relates to the field of disorders of the peripheral or central nervous system, in particular Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the present invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell, and in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of said disorders.

Patent Publication Number: EP2440934

Year filing: 2010

Year approval: 2014

Year publication: 2014

Status: Assigned

Technology domains: Analysis of biological materials

Validated for IOF-key: Yes

Attributed to: Associatie KULeuven